Page last updated: 2024-11-11

macluraxanthone b

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

macluraxanthone B: from the plant Maclura tinctoria; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

macluraxanthone B : A member of the class of xanthones that is 9H-xanthen-9-one substituted by hydroxy groups at positions 1, 3, 6 and 7, a dimethylallyl group at position 2 and a prenyl group at position 4. Isolated from Maclura tinctoria and Cudrania tricuspidata, it exhibits anti-HIV and antineoplastic activity. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

FloraRankFlora DefinitionFamilyFamily Definition
MacluragenusA plant genus of the family MORACEAE. Members contain maclurin, antifungal chalcones, and other compounds.[MeSH]MoraceaeThe mulberry plant family of the order Urticales, subclass Hamamelidae, class Magnoliopsida. They have milky latex and small, petalless male or female flowers.[MeSH]
Maclura tinctoriaspecies[no description available]MoraceaeThe mulberry plant family of the order Urticales, subclass Hamamelidae, class Magnoliopsida. They have milky latex and small, petalless male or female flowers.[MeSH]

Cross-References

ID SourceID
PubMed CID5353737
CHEMBL ID370126
CHEBI ID66649
MeSH IDM0378339

Synonyms (14)

Synonym
nsc692942
chloroxanthone a
2-(1,1-dimethylallyl)-1,3,6,7-tetrahydroxy-4-(3-methylbut-2-enyl)xanthen-9-one
macluraxanthone b
2-(1,1-dimethyl-allyl)-1,3,6,7-tetrahydroxy-4-(3-methyl-but-2-enyl)-xanthen-9-one
nsc-692942
chebi:66649 ,
CHEMBL370126 ,
1,3,6,7-tetrahydroxy-2-(2-methylbut-3-en-2-yl)-4-(3-methylbut-2-enyl)xanthen-9-one
1,3,6,7-tetrahydroxy-4-(3-methylbut-2-enyl)-2-(2-methylbut-3-en-2-yl)-9h-xanthen-9-one
2,3,6,8-tetrahydroxy-5-(3-methylbut-2-enyl)-7-(2-methylbut-3-en-2-yl)-9h-xanthen-9-one
bdbm50175012
1,3,6,7-tetrahydroxy-2-(2-methylbut-3-en-2-yl)-4-(3-methylbut-2-en-1-yl)-9h-xanthen-9-one
Q27135267
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
metaboliteAny intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.
anti-HIV agentAn antiviral agent that destroys or inhibits the replication of the human immunodeficiency virus.
antineoplastic agentA substance that inhibits or prevents the proliferation of neoplasms.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
xanthonesAny member of the class of xanthenes based on a xanthone skeleton.
phenolsOrganic aromatic compounds having one or more hydroxy groups attached to a benzene or other arene ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Sterol O-acyltransferase 2Homo sapiens (human)IC50 (µMol)112.00000.11003.20369.2000AID276035
Sterol O-acyltransferase 1Homo sapiens (human)IC50 (µMol)96.00000.02501.79758.0000AID276034
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (9)

Processvia Protein(s)Taxonomy
cholesterol metabolic processSterol O-acyltransferase 2Homo sapiens (human)
macrophage derived foam cell differentiationSterol O-acyltransferase 2Homo sapiens (human)
cholesterol storageSterol O-acyltransferase 2Homo sapiens (human)
intestinal cholesterol absorptionSterol O-acyltransferase 2Homo sapiens (human)
cholesterol effluxSterol O-acyltransferase 2Homo sapiens (human)
very-low-density lipoprotein particle assemblySterol O-acyltransferase 2Homo sapiens (human)
low-density lipoprotein particle clearanceSterol O-acyltransferase 2Homo sapiens (human)
cholesterol homeostasisSterol O-acyltransferase 2Homo sapiens (human)
cholesterol metabolic processSterol O-acyltransferase 1Homo sapiens (human)
cholesterol metabolic processSterol O-acyltransferase 1Homo sapiens (human)
macrophage derived foam cell differentiationSterol O-acyltransferase 1Homo sapiens (human)
cholesterol storageSterol O-acyltransferase 1Homo sapiens (human)
cholesterol effluxSterol O-acyltransferase 1Homo sapiens (human)
very-low-density lipoprotein particle assemblySterol O-acyltransferase 1Homo sapiens (human)
low-density lipoprotein particle clearanceSterol O-acyltransferase 1Homo sapiens (human)
cholesterol homeostasisSterol O-acyltransferase 1Homo sapiens (human)
positive regulation of amyloid precursor protein biosynthetic processSterol O-acyltransferase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (6)

Processvia Protein(s)Taxonomy
fatty-acyl-CoA bindingSterol O-acyltransferase 2Homo sapiens (human)
sterol O-acyltransferase activitySterol O-acyltransferase 2Homo sapiens (human)
protein bindingSterol O-acyltransferase 2Homo sapiens (human)
cholesterol bindingSterol O-acyltransferase 2Homo sapiens (human)
acyltransferase activitySterol O-acyltransferase 2Homo sapiens (human)
cholesterol O-acyltransferase activitySterol O-acyltransferase 2Homo sapiens (human)
fatty-acyl-CoA bindingSterol O-acyltransferase 1Homo sapiens (human)
sterol O-acyltransferase activitySterol O-acyltransferase 1Homo sapiens (human)
protein bindingSterol O-acyltransferase 1Homo sapiens (human)
cholesterol bindingSterol O-acyltransferase 1Homo sapiens (human)
cholesterol O-acyltransferase activitySterol O-acyltransferase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (4)

Processvia Protein(s)Taxonomy
endoplasmic reticulumSterol O-acyltransferase 2Homo sapiens (human)
endoplasmic reticulum membraneSterol O-acyltransferase 2Homo sapiens (human)
brush borderSterol O-acyltransferase 2Homo sapiens (human)
endoplasmic reticulum membraneSterol O-acyltransferase 2Homo sapiens (human)
endoplasmic reticulumSterol O-acyltransferase 1Homo sapiens (human)
endoplasmic reticulum membraneSterol O-acyltransferase 1Homo sapiens (human)
membraneSterol O-acyltransferase 1Homo sapiens (human)
endoplasmic reticulum membraneSterol O-acyltransferase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (18)

Assay IDTitleYearJournalArticle
AID257307Hydroxyl radical scavenging activity of Cudriana tricuspidata extracts2005Bioorganic & medicinal chemistry letters, Dec-15, Volume: 15, Issue:24
Antioxidant and cytotoxic activities of xanthones from Cudrania tricuspidata.
AID257309Cytotoxicity against human cancer HL60 cell line by MTT assay2005Bioorganic & medicinal chemistry letters, Dec-15, Volume: 15, Issue:24
Antioxidant and cytotoxic activities of xanthones from Cudrania tricuspidata.
AID257311Cytotoxicity against human cancer AGS cell line by MTT assay2005Bioorganic & medicinal chemistry letters, Dec-15, Volume: 15, Issue:24
Antioxidant and cytotoxic activities of xanthones from Cudrania tricuspidata.
AID257310Cytotoxicity against human cancer SKOV3 cell line by MTT assay2005Bioorganic & medicinal chemistry letters, Dec-15, Volume: 15, Issue:24
Antioxidant and cytotoxic activities of xanthones from Cudrania tricuspidata.
AID378244Cytotoxicity against human CEM-SS cells2000Journal of natural products, Nov, Volume: 63, Issue:11
HIV-Inhibitory prenylated xanthones and flavones from Maclura tinctoria.
AID276034Inhibition of human ACAT1 expressed in Hi5 cells2006Bioorganic & medicinal chemistry letters, Nov-01, Volume: 16, Issue:21
Anti-atherosclerotic and anti-inflammatory activities of catecholic xanthones and flavonoids isolated from Cudrania tricuspidata.
AID1169597Antiproliferative activity against rat HSC-T6 cells assessed as reduction in cell viability2014Journal of natural products, Nov-26, Volume: 77, Issue:11
Antiproliferative prenylated xanthones and benzophenones from the roots of Cudrania tricuspidata in HSC-T6 cells.
AID257308Cytotoxicity against human cancer HT29 cell line by MTT assay2005Bioorganic & medicinal chemistry letters, Dec-15, Volume: 15, Issue:24
Antioxidant and cytotoxic activities of xanthones from Cudrania tricuspidata.
AID310609Inhibition of bakers yeast alpha-glucosidase by spectrophotometry2007Bioorganic & medicinal chemistry letters, Dec-01, Volume: 17, Issue:23
Xanthones from Cudrania tricuspidata displaying potent alpha-glucosidase inhibition.
AID276035Inhibition of human ACAT2 expressed in Hi5 cells2006Bioorganic & medicinal chemistry letters, Nov-01, Volume: 16, Issue:21
Anti-atherosclerotic and anti-inflammatory activities of catecholic xanthones and flavonoids isolated from Cudrania tricuspidata.
AID257306Superoxide radical scavenging activity of Cudriana tricuspidata extracts2005Bioorganic & medicinal chemistry letters, Dec-15, Volume: 15, Issue:24
Antioxidant and cytotoxic activities of xanthones from Cudrania tricuspidata.
AID378243Antiviral activity against HIV12000Journal of natural products, Nov, Volume: 63, Issue:11
HIV-Inhibitory prenylated xanthones and flavones from Maclura tinctoria.
AID378560Cytotoxicity against human SKOV3 cells after 48 hrs by SRB assay2005Journal of natural products, Mar, Volume: 68, Issue:3
Cytotoxic xanthones from Cudrania tricuspidata.
AID257314Cytotoxic activity in HL60 by DNA fragmentation assay2005Bioorganic & medicinal chemistry letters, Dec-15, Volume: 15, Issue:24
Antioxidant and cytotoxic activities of xanthones from Cudrania tricuspidata.
AID257312Cytotoxicity against human cancer A549 cell line by MTT assay2005Bioorganic & medicinal chemistry letters, Dec-15, Volume: 15, Issue:24
Antioxidant and cytotoxic activities of xanthones from Cudrania tricuspidata.
AID257313DPPH radical scavenging activity of Cudriana tricuspidata extracts2005Bioorganic & medicinal chemistry letters, Dec-15, Volume: 15, Issue:24
Antioxidant and cytotoxic activities of xanthones from Cudrania tricuspidata.
AID378559Cytotoxicity against human A549 cells after 48 hrs by SRB assay2005Journal of natural products, Mar, Volume: 68, Issue:3
Cytotoxic xanthones from Cudrania tricuspidata.
AID276033Antioxidant activity against human plasma LDL oxidation by TBARS assay2006Bioorganic & medicinal chemistry letters, Nov-01, Volume: 16, Issue:21
Anti-atherosclerotic and anti-inflammatory activities of catecholic xanthones and flavonoids isolated from Cudrania tricuspidata.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's5 (71.43)29.6817
2010's1 (14.29)24.3611
2020's1 (14.29)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.93

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.93 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index5.01 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.93)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]